The synergistic anion-binding sites of human transferrin: chemical and physiological effects of site-directed mutagenesis.
A defining feature of all transferrins is the absolute dependence of iron binding on the concomitant binding of a synergistic anion, normally but not necessarily carbonate. Acting as a bridging ligand between iron and protein, it completes the coordination requirements of iron to lock the essential metal in its binding site. To investigate the role of the synergistic anion in the iron-binding and iron-donating properties of human transferrin, a bilobal protein with an iron binding site in each lobe, we have selectively mutated the anion-binding threonine and arginine ligands that form an essential part of the electrostatic and hydrogen-bonding network holding the synergistic anion to the protein. Preservation of either ligand is sufficient to maintain anion binding, and therefore iron binding, in the mutated lobe. Arginine is a stronger ligand than threonine, and its loss weakens carbonate and therefore iron binding, but maintains the ability of nitrilotriacetate to serve as a carbonate surrogate. Replacement of both ligands abolishes anion binding and consequently iron binding in the affected lobe. Loss of anion binding in either lobe results in a monoferric protein binding iron in normal fashion only in the opposite lobe. Both monoferric proteins are capable of transferrin receptor-dependent binding and iron donation to K562 cells, but with diminished receptor occupancy by the protein bearing iron only in the N-lobe.
Zak
Olga
O
Department of Physiology and Biophysics, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA.
Ikuta
Katsuya
K
Aisen
Philip
P
D000409:Alanine / Q000235:genetics / Q000378:metabolism; D000838:Anions / Q000378:metabolism; D001120:Arginine / Q000235:genetics / Q000378:metabolism; D001665:Binding Sites / Q000235:genetics; D002255:Carbonic Acid / Q000378:metabolism; D004357:Drug Synergism; D004578:Electron Spin Resonance Spectroscopy; D006801:Humans; D007501:Iron / Q000378:metabolism; D020014:K562 Cells / Q000378:metabolism; D007700:Kinetics; D016297:Mutagenesis, Site-Directed / Q000502:physiology*; D009571:Nitrilotriacetic Acid / Q000378:metabolism; D010446:Peptide Fragments / Q000737:chemistry / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D011994:Recombinant Proteins / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D012694:Serine / Q000235:genetics / Q000378:metabolism; D013053:Spectrophotometry; D013912:Threonine / Q000235:genetics / Q000378:metabolism; D014168:Transferrin / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism / Q000502:physiology*
D000838:Anions; C031138:N-terminal monoferrictransferrin; D010446:Peptide Fragments; D011994:Recombinant Proteins; D014168:Transferrin; D013912:Threonine; D012694:Serine; D002255:Carbonic Acid; D001120:Arginine; D007501:Iron; D009571:Nitrilotriacetic Acid; D000409:Alanine